Objectives During the last decades, a changing epidemiological pattern of genital herpes simplex virus (HSV) infection has emerged. Primary infection is now caused as often by HSV-1 as by HSV-2. Once established, HSV can be reactivated leading to recurrent mucocutaneous lesions as well as meningitis. Why some otherwise immune-competent individuals experience severe and frequent recurrences is not known, and the immunological mechanism underlying recurrent symptomatic HSV infection is not fully understood. In this study, we investigate and characterise the immune response of patients with first episode of HSV genital infection and its relation to the frequency of symptomatic recurrences.
Methods In this cohort study, clinical and immunological data were collected from 29 patients who were followed 1 year after presenting with a first episode of genital or meningeal HSV infection. They were classified by PCR and serology as those with primary HSV-1, primary HSV-2 and non-primary HSV-2 infection.
Results HSV-specific interleukin(Il)-4 and Il-10 responses at first visit were higher in primary infected HSV-2 infected patients experiencing lower numbers of recurrences during subsequent year.
Conclusions The median number of recurrences following primary HSV-2 genital infection may partly be predicted by the strength of an early HSV-specific IL-4 and IL-10 response.
- GENITAL HERPES
- HERPES SIMPLEX (CLINICAL)
- INFECTION CONTROL
- HSV VIROLOGY
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Handling editor Jackie A Cassell
Contributors HG, AW, KK, LB, EA and EF-R: initiated the study and was involved in the design and implementation. EF-R, DS, LB and HG: collaborated in the writing and analyses of the manuscript. HG, LB, DS, FA and KF: monitored data and performed statistical analyses. HG, KK, LB, DS, EFR and J-ÅL: participated in the interpretations of the results. HG, EFR, LB, EA, J-ÅL and TB: revised the manuscript before submission. All authors reviewed and approved the manuscript.
Funding This study was supported from the regional agreement on medical training and clinical research (ALF) between Stockholm county council and Karolinska Institutet, Stockholm.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Regional Ethical Review Board in Stockholm, Karolinska Institutet 2005/171-31.
Provenance and peer review Not commissioned; externally peer reviewed.